Last reviewed · How we verify

NCT06250348: ENOBARDS

Exhaled Nitric Oxide : Biomarker of Acute Respiratory Distress Syndrome

Completed Last updated 30 March 2025
What this trial tests

trial testing Non invasive measure of endogenous exhaled Nitric Oxyde in exhaled gaz, by a laser spectrometer in ARDS, Human in 20 participants. Completed in 5 January 2025.

Timeline
15 February 2024
Primary endpoint
1 September 2024
5 January 2025

Quick facts

Lead sponsorUniversity Hospital, Grenoble
StatusCompleted
Study typeOBSERVATIONAL
Enrollment20
Start date15 February 2024
Primary completion1 September 2024
Estimated completion5 January 2025
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Grenoble

Who can join

18 and older, any sex, with ARDS, Human or Nitric Oxyde. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to see if endogenous exhaled Nitric Oxyde (eNO) concentrations measured are significantly higher in ARDS patients admitted in ICU ; compared to control subjects in good health with no lung disease or global inflammation, operated under general anesthesia (i.e. intubated and ventilated) for thyroid or parathyroid.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for ARDS, Human

Currently open trials in the same condition.

Other University Hospital, Grenoble trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06250348.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing